Mark Ritter
Professor and Vice Chair
600 Highland Avenue
K4/B100
Madison, WI 53792
Telephone: 608-263-8500
Fax: N/A
E-mail:
2008-present Professor of Human Oncology, Department of Human Oncology, Section of Radiation Oncology, University of Wisconsin Medical School, Madison, Wisconsin
1995-present Associate Professor of Medical Physics, Department of Medical Physics, University of Wisconsin Medical School, Madison, Wisconsin
1994-present Associate Professor of Human Oncology, Department of Human Oncology, Section of Radiation Oncology, University of Wisconsin Medical School, Madison, Wisconsin
1988-94 Assistant Professor of Human Oncology, Department of Human Oncology, Section of Radiation Oncology, University of Wisconsin Medical School, Madison, Wisconsin
1985-88 Resident, Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
1984-85 Intern, Presbyterian-University of Pennsylvania Medical Center, Philadelphia, Pennsylvania
1978-82 Assistant Professor of Radiation Biology in Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
1976-77 Research Associate, Department of Physiology, Harvard School of Public Health, Boston, Massachusetts
Administrative Support
1966-70 B.S., Physics, University of San Francisco 1970-71 M.S., Nuclear Engineering, University of California, Berkeley 1971-76 Ph.D., Nuclear Engineering, University of California, Berkeley 1982-84 M.D., University of Miami School of Medicine
Khor LY, Moughan J, Al-Saleem T, Hammond EH, Venkatesan V,Rosenthal SA, Ritter MA, Sandler HM, Hanks GE, Shipley WU, Pollack A. Bcl-2 and bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy in RTOG 92-02. Clin Cancer Res 13: 3585-90, 2007.
Allen GW, Howard AR, Jarrard DF, Ritter MA. Management of prostate cancer recurrences after radiation therapy - Brachytherapy as a salvage option. Cancer 110: 1405-16, 2007.
Hutson P, Oettel K, Douglas J, Ritter M , Messing E, Staab MJ, Alberti D, Horvath D, Wilding G. Effect of Medical Castration on CYP3A4 Enzyme Activity using the Erythromycin Breath Test. Cancer Chemotherapy and Pharmacology, 63: 373-77, 2008.
M. A. Ritter, J. D. Forman, P. A. Kupelian, D. G. Petereit, C. Lawton, W. Walker, J. F. Fowler, W. A. Tome. A Phase I/II Trial of Dose-per-Fraction Escalation for Prostate Cancer. Int J Radiat Biol Oncol Phys. 69, S174, 2007.
Wong G, Palazzi-Churas K, Jarrard D, Paolone D, Graf A, Hedican S, Wegenke J, Ritter M. Salvage hypofractionated radiation therapy for biochemically recurrent prostate cancer following radical prostatectomy. Int J Radiat Oncol Biol Phys 70: 449-55, 2008.
Ritter MA, FormanJD, Petereit DG, Kupelian PA, Lawton C, Walker W, Fowler JF, Chappell RJ, Tome WA. A multi-institutional phase I/II trial of radiation hypofractionation in localized prostate cancer, in preparation.
Khor LY, Bae K, Pollack A, Hammond EH, Venkatesan V , Rosenthal SA, Ritter MA, Sandler HM, Hanks GE, Shipley WU, Dicker AP. Cox-2 Expression Predicts Prostate Cancer Outcome: An Analysis of Radiation Therapy Oncology Group Trial 92-02. Lancet Oncol 8: 921-20, 2007.
Ritter, MA. Prognostic and Predictive Markers in Radiation Therapy: Focus on Prostate Cancer, in: Radiation Oncology Advances. Ed Bentzen et al. Springer, 2008.
Hawk E, Compton C, Lee F, Grochow L, Niederhuber JE, Ritter MA: Colon Cancer. In the textbook: Clinical Oncology, 4th ed. Ed. Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE. Churchill Livingstone, Philadelphia PA , 2007.
Ritter MA: Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer. In: Hypofractionation. Sem. Radiat. Oncol. 2009 in press.
Treatment of prostate, bladder, testicular, esophageal, pancreatic and colorectal cancer
Clinical trials in prostate, esophageal and rectal cancer.
Molecular predictors of treatment response in prostate and esophageal cancers
National Institutes of Health, CA-60103, Tumor kinetics in head and neck cancer, MA Ritter, Principal Investigator, 07/01/93-06/30/97.
National Institutes of Health, CA-60261, Radiation therapy 3-D dose escalation for prostate cancer, 06/01/93-05/31/98, MA Ritter, Principal Investigator.
National Institutes of Health, CA-52692, Radiotherapy dose planning using Monte Carlo simulation, 12/01/93-11/30/96, MA Ritter, Co- Investigator.
National Institutes of Health, CA-70838, Phase II trial of accelerated concomitant boost radiation therapy in bladder cancer, 07/15/96-06/30/98, MA Ritter, Co-Investigator.
National Institutes of Health, CA-75377, Proliferation-targeted therapy in carcinoma of the cervix, 07/01/97-12/31/00, MA Ritter, Principal Investigator.
National Institute of Health PO-1, Improving cancer outcome with adaptive helical tomotherapy, 04/1/01-03/31/07, MA Ritter, project leader, 20% effort, 20% salary.
Department of Defense PC010030, Molecular Markers as Predictors of Radiation Response in Prostate Cancer, 09/01/01-12/31/04, MA Ritter. Principal Investigator.
National Institutes of Health, U56 CA99010, Enhancing Native American Participation in RT Trials, 09/27/02-08/31/08, D Petereit, Principal Investigator; MA Ritter, Co-Investigator.
National Institutes of Health, RO1CA109556, Biomarkers of Prostate Cancer Radiation Outcome, 04/01/05 – 03/31/09, MA Ritter, Principal Investigator.
National Institutes of Health, R01CA106835-01, Hypofractionated IMRT for Localized Prostate Cancer, 07/01/05 – 06/30/09, MA Ritter, Principal Investigator.
Amgen Pharmaceuticals, A Phase I/II Trial of Panitumumab/Cisplatin/Irinotecan combined with radiation Preoperatively for Patients with Locally Advanced Esophageal Cancer. MA Ritter, PI.